UniQure to Seek FDA Approval for Breakthrough Huntington’s Gene Therapy
UniQure (NASDAQ: QURE) said Wednesday it plans to file for FDA approval of its experimental Huntington’s disease gene therapy in the third quarter.
The planned submission follows new feedback from the FDA on how the company can pursue accelerated approval. UniQure said the agency indicated that three-year data from a Phase 1/2 study could be used to support a marketing application. Huntington’s disease is a rare inherited disorder that progressively damages nerve cells in the brain. UniQure’s therapy is administered directly into the brain through a surgical procedure that lasts several hours.
The company has relied on a study design that compares treated patients with the typical course of Huntington’s disease using an outside database. UniQure has said a sham-surgery control group would be unethical because patients would undergo an invasive procedure without receiving the experimental treatment.
UniQure said the Phase 1/2 trial showed a 75% slowing in disease progression when patients who received the therapy were compared with the external control.
An FDA official confirmed that the agency and UniQure have agreed on a path for submitting a marketing application and seeking accelerated approval based on the clinical data already available. The official said the agency remains committed to working with UniQure on a regulatory path for Huntington’s patients and families while upholding its scientific standards.
The latest FDA feedback differs from the agency’s position earlier this year. In March, UniQure said regulators had concluded that its external-control data would not support an application. A senior FDA official also told reporters at the time that the company should conduct a placebo-controlled trial to show that the treatment helps patients.
The dispute became public during a broader period of regulatory reversals affecting rare disease drug developers. In a February interview, then-FDA Commissioner Marty Makary described an unnamed treatment and said the agency was being pressured to approve it despite showing “no benefit.” UniQure later said the FDA did not agree that its trial data were sufficient to support a filing.
Makary left the FDA in May. Other senior agency officials also departed, including former Center for Biologics Evaluation and Research director Vinay Prasad and former Center for Drug Evaluation and Research director Tracy Beth Hoeg.
Shares of UniQure rose 70% on Wednesday after the company disclosed the updated regulatory path.
Under accelerated approval, UniQure’s therapy could reach the market while the company conducts another study to confirm its benefit. UniQure said the FDA wants the company to align with the agency on that study’s design, including a comparison against the current standard of care rather than a sham procedure.
The company said it expects to finalize the confirmatory study plan before filing its application.
About UniQure
UniQure (NASDAQ: QURE) is a biotechnology company focused on developing gene therapies for severe genetic diseases. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands, with operations in the United States.
At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.